Hovione and Invion will partner on the development of Invion's INV104 zafirlukast DPI for the treatment of asthma, the companies have announced. Hovione will provide the device as well as particle engineering, formulation, and manufacturing services; Invion will take responsibility for pre-clinical and clinical development as well as regulatory submissions. Hovione … [Read more...] about Invion and Hovione partner on inhaled zafirlukast for asthma
Business
Pulmatrix gets two new patents for its iSPERSE inhalation powder technology
The US Patent and Trademark Office has issued Pulmatrix two new patents, US Patent No. 8,992,983, "Respirably dry powder comprising calcium lactate, sodium chloride and leucine" and US Patent No. 9,061,352, "Dry powder formulations and methods for treating pulmonary diseases," the company said. Pulmatrix now has 36 patents covering technology related to the iSPERSE … [Read more...] about Pulmatrix gets two new patents for its iSPERSE inhalation powder technology
Adherium (formerly Nexus6) partners with AstraZeneca
Smartinhaler maker Adherium (formerly Nexus6) has announced a new deal to provide AstraZeneca with devices and sensors for use in asthma and COPD patient support programs. AstraZeneca has already used the Adherium technology in clinical trials. Studies have verified that Smartinhaler use significantly increases adherence to asthma medications both in children and … [Read more...] about Adherium (formerly Nexus6) partners with AstraZeneca
Acorda gets Gates Foundation grant for dry powder lung surfactant development
Acorda Therapeutics has announced that it received a $1.4 million grant from the Bill & Melinda Gates Foundation for development of a dry powder lung surfactant for the treatment of neonatal respiratory distress syndrome (RDS) based on its ARCUS inhalation platform, as well as a delivery system. The company will develop the formulation in conjunction with the … [Read more...] about Acorda gets Gates Foundation grant for dry powder lung surfactant development
Inhalation Sciences adds new investors
Swedish-based Inhalation Sciences AB (ISAB) has added new minority shareholders Stockholms Affärsänglar (STOAF) and Almi Invest, "with a significant initial capital investment," the company said. According to ISAB, that investment is the first phase out of three. ISAB's PreciseInhale system is used to aerosolize very small amounts of inhalable dry powders for … [Read more...] about Inhalation Sciences adds new investors
DuoResp Spiromax wins silver Medical Design Excellence Award
Teva Pharmaceutical's DuoResp Spiromax multidose DPI has won a Silver award at the 2015 Medical Design Excellence Awards (MDEA), with Gerresheimer receiving credit as a supplier. DuoResp Spiromax received European marketing authorization in April 2014. Teva Global Specialty Medicines President and CEO Rob Koremans commented, "Innovative, patient-focused design is … [Read more...] about DuoResp Spiromax wins silver Medical Design Excellence Award
Israeli patent issued for AAT pulmonary delivery system
The Israeli Patent Office has issued Patent No. 193318, “System for Pulmonary Delivery of Alpha-1 Proteinase Inhibitor,” to Kamada and PARI Pharma, Kamada has announced. The patent relates to delivery of Kamada’s inhaled alpha-1 proteinase inhibitor (AAT) using a custom eFlow nebulizer from PARI. Kamada CEO Amir London commented, “We continue to fortify our … [Read more...] about Israeli patent issued for AAT pulmonary delivery system
Boehringer Ingelheim launches Stiolto Respimat in the US
Boehringer Ingelheim Pharmaceuticals has announced the availability of the Stiolto Respimat tiotropium bromide/olodaterol soft mist inhaler in the United States. Stiolto Respimat was approved by the FDA for the treatment of COPD in May 2015. Pharmacies are selling the inhaler for about $325-$350. The company is offering a savings card to cover a co-pays over 12 … [Read more...] about Boehringer Ingelheim launches Stiolto Respimat in the US
Novoteris gets $2.8 million from Cystic Fibrosis Foundation Therapeutics for inhaled nitric oxide
US-based Novoteris has received a $2.8 million award from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) for development of Thiolanox inhaled nitric oxide therapy for the treatment of bacterial lung infections in cystic fibrosis patients. The company said that it plans to use the funding for a Phase 2b study which is expected start by the third quarter of 2015. … [Read more...] about Novoteris gets $2.8 million from Cystic Fibrosis Foundation Therapeutics for inhaled nitric oxide
Alexza to stop manufacturing Adasuve for its partners
Alexza Pharmaceuticals has announced that it will suspend production of Adasuve inhaled loxapine for its partners Ferrer and Teva after the third quarter of 2015 "to reduce Alexza's underutilized manufacturing capacity, overhead expenses and related costs, while fulfilling the supply requirements of its commercial partners." The company says that during the … [Read more...] about Alexza to stop manufacturing Adasuve for its partners